Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014

Authors: Qiwen Yang, Hui Zhang, Yao Wang, Zhipeng Xu, Ge Zhang, Xinxin Chen, Yingchun Xu, Bin Cao, Haishen Kong, Yuxing Ni, Yunsong Yu, Ziyong Sun, Bijie Hu, Wenxiang Huang, Yong Wang, Anhua Wu, Xianju Feng, Kang Liao, Yanping Luo, Zhidong Hu, Yunzhuo Chu, Juan Lu, Jianrong Su, Bingdong Gui, Qiong Duan, Shufang Zhang, Haifeng Shao, Robert E. Badal

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

The objective of this study was to investigate the distribution and susceptibility of aerobic and facultative Gram-negative bacilli isolated from Chinese patients with UTIs collected within 48 h (community acquired, CA) or after 48 h (hospital acquired, HA) of hospital admission.

Methods

From 2010 to 2014, the minimum inhibitory concentrations (MICs) of 12 antibiotics for 4,332 aerobic and facultative Gram-negative bacilli, sampled in 21 hospitals in 16 cities, were determined by the broth microdilution method.

Results

Enterobacteriaceae composed 88.5% of the total isolates, with Escherichia coli (E. coli) (63.2%) the most commonly isolated species, followed by Klebsiella pneumoniae (K. pneumoniae) (12.2%). Non-Enterobacteriaceae accounted for only 11.5% of all isolates and included mainly Pseudomonas aeruginosa (P. aeruginosa) (6.9%) and Acinetobacter baumannii (A. baumannii) (3.3%). Among the antimicrobial agents tested, the susceptibility rates of E.coli to the two carbapenems, ertapenem and imipenem as well as amikacin and piperacillin-tazobactam ranged from 92.5 to 98.7%. Against K. pneumonia, the most potent antibiotics were imipenem (92.6% susceptibility), amikacin (89.2% susceptibility) and ertapenem (87.9% susceptibility).
Although non-Enterobacteriaceae did not show high susceptibilities to the 12 common antibiotics, amikacin exhibited the highest in vitro activity against P. aeruginosa over the 5-year study period, followed by piperacillin-tazobactam, imipenem, ceftazidime, cefepime, ciprofloxacin, and levofloxacin. The Extended Spectrum Beta-Lactamase (ESBL) rates decreased slowly during the 5 years in E. coli from 68.6% in 2010 to 59.1% in 2014, in K. pneumoniae from 59.7 to 49.2%, and in Proteus mirabilis (P. mirabilis) from 40.0 to 26.1%. However, the ESBL rates were different in 5 regions of China (Northeast, North, East, South and Middle-China).

Conclusion

E. coli and K. pneumonia were the major pathogens causing UTIs and carbapenems and amikacin retained the highest susceptibility rates over the 5-year study period, indicating that they are good drug choices for empirical therapies, particularly of CA UTIs in China.
Literature
1.
go back to reference Bi XC, Zhang B, Ye YK, He HC, Han ZD, Dai QS, et al. Pathogen incidence and antibiotic resistance patterns of catheter-associated urinary tract infection in children. J Chemother. 2009;21:661–5.CrossRefPubMed Bi XC, Zhang B, Ye YK, He HC, Han ZD, Dai QS, et al. Pathogen incidence and antibiotic resistance patterns of catheter-associated urinary tract infection in children. J Chemother. 2009;21:661–5.CrossRefPubMed
2.
go back to reference Qiao LD, Chen S, Yang Y, Zhang K, Zheng B, Guo HF, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open. 2013;3:e004152.CrossRefPubMedPubMedCentral Qiao LD, Chen S, Yang Y, Zhang K, Zheng B, Guo HF, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open. 2013;3:e004152.CrossRefPubMedPubMedCentral
3.
go back to reference Hertz FB, Schonning K, Rasmussen SC, Littauer P, Knudsen JD, Lobner-Olesen A, et al. Epidemiological factors associated with ESBL- and non ESBL-producing E. coli causing urinary tract infection in general practice. Infect Dis (Lond). 2016;48:241–5.CrossRef Hertz FB, Schonning K, Rasmussen SC, Littauer P, Knudsen JD, Lobner-Olesen A, et al. Epidemiological factors associated with ESBL- and non ESBL-producing E. coli causing urinary tract infection in general practice. Infect Dis (Lond). 2016;48:241–5.CrossRef
4.
go back to reference Guembe M, Cercenado E, Alcala L, Marin M, Insa R, Bouza E. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003–2007. Rev Esp Quimioter. 2008;21:166–73.PubMed Guembe M, Cercenado E, Alcala L, Marin M, Insa R, Bouza E. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003–2007. Rev Esp Quimioter. 2008;21:166–73.PubMed
5.
go back to reference Stapleton AE. Urinary tract infection pathogenesis: host factors. Infect Dis Clin North Am. 2014;28:149–59.CrossRefPubMed Stapleton AE. Urinary tract infection pathogenesis: host factors. Infect Dis Clin North Am. 2014;28:149–59.CrossRefPubMed
6.
go back to reference Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1–13.CrossRefPubMed Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1–13.CrossRefPubMed
7.
go back to reference Wellington EM, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, et al. The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. Lancet Infect Dis. 2013;13:155–65.CrossRefPubMed Wellington EM, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, et al. The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. Lancet Infect Dis. 2013;13:155–65.CrossRefPubMed
8.
go back to reference Caccamo M, Perilli M, Celenza G, Bonfiglio G, Tempera G, Amicosante G. Occurrence of extended spectrum beta-lactamases among isolates of Enterobacteriaceae from urinary tract infections in southern Italy. Microb Drug Resist. 2006;12:257–64.CrossRefPubMed Caccamo M, Perilli M, Celenza G, Bonfiglio G, Tempera G, Amicosante G. Occurrence of extended spectrum beta-lactamases among isolates of Enterobacteriaceae from urinary tract infections in southern Italy. Microb Drug Resist. 2006;12:257–64.CrossRefPubMed
9.
go back to reference Al Yousef SA, Younis S, Farrag E, Moussa H, Bayoumi FS, Ali AM. Clinical and laboratory profile of urinary tract infections associated with extended Spectrum beta-Lactamase producing Escherichia coli and Klebsiella pneumoniae. Ann Clin Lab Sci. 2016;46:393–400.PubMed Al Yousef SA, Younis S, Farrag E, Moussa H, Bayoumi FS, Ali AM. Clinical and laboratory profile of urinary tract infections associated with extended Spectrum beta-Lactamase producing Escherichia coli and Klebsiella pneumoniae. Ann Clin Lab Sci. 2016;46:393–400.PubMed
10.
go back to reference Bonkat G, Muller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, et al. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates. World J Urol. 2013;31:1427–32.CrossRefPubMed Bonkat G, Muller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, et al. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates. World J Urol. 2013;31:1427–32.CrossRefPubMed
11.
go back to reference Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005–2007: results from the SMART study. Int J Antimicrob Agents. 2009;34:585–8.CrossRefPubMed Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005–2007: results from the SMART study. Int J Antimicrob Agents. 2009;34:585–8.CrossRefPubMed
12.
go back to reference Institute CaLS. Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th ed. Wayne: PA:CLSI document M7-A9; 2012. Institute CaLS. Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th ed. Wayne: PA:CLSI document M7-A9; 2012.
13.
go back to reference Institute CaLS. Performance standards for antimicrobial susceptibility testing. Twenty-fifth informational supplement. Wayne: PA:Document M100-S25; 2015. Institute CaLS. Performance standards for antimicrobial susceptibility testing. Twenty-fifth informational supplement. Wayne: PA:Document M100-S25; 2015.
14.
go back to reference Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious diseases Society of America and the European society for microbiology and infectious diseases. Clin Infect Dis. 2011;52:e103–20.CrossRefPubMed Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious diseases Society of America and the European society for microbiology and infectious diseases. Clin Infect Dis. 2011;52:e103–20.CrossRefPubMed
15.
go back to reference Zhao L, Chen X, Zhu X, Yang W, Dong L, Xu X, et al. Prevalence of virulence factors and antimicrobial resistance of uropathogenic Escherichia coli in Jiangsu province (China). Urology. 2009;74:702–7.CrossRefPubMed Zhao L, Chen X, Zhu X, Yang W, Dong L, Xu X, et al. Prevalence of virulence factors and antimicrobial resistance of uropathogenic Escherichia coli in Jiangsu province (China). Urology. 2009;74:702–7.CrossRefPubMed
16.
go back to reference Hope R, Potz NA, Warner M, Fagan EJ, Arnold E, Livermore DM. Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae. J Antimicrob Chemother. 2007;59:110–3.CrossRefPubMed Hope R, Potz NA, Warner M, Fagan EJ, Arnold E, Livermore DM. Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae. J Antimicrob Chemother. 2007;59:110–3.CrossRefPubMed
17.
go back to reference Guo W, He Q, Wang Z, Wei M, Yang Z, Du Y, et al. Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008–2013 at a tertiary hospital in Shanghai, China. Am J Infect Control. 2015;43:358–64.CrossRefPubMed Guo W, He Q, Wang Z, Wei M, Yang Z, Du Y, et al. Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008–2013 at a tertiary hospital in Shanghai, China. Am J Infect Control. 2015;43:358–64.CrossRefPubMed
18.
go back to reference Ding H, Yang Y, Wei J, Fan S, Yu S, Yao K, et al. Influencing the use of antibiotics in a Chinese pediatric intensive care unit. Pharm World Sci. 2008;30:787–93.CrossRefPubMed Ding H, Yang Y, Wei J, Fan S, Yu S, Yao K, et al. Influencing the use of antibiotics in a Chinese pediatric intensive care unit. Pharm World Sci. 2008;30:787–93.CrossRefPubMed
19.
go back to reference Zou YM, Ma Y, Liu JH, Shi J, Fan T, Shan YY, et al. Trends and correlation of antibacterial usage and bacterial resistance: time series analysis for antibacterial stewardship in a Chinese teaching hospital (2009–2013). Eur J Clin Microbiol Infect Dis. 2015;34:795–803.CrossRefPubMed Zou YM, Ma Y, Liu JH, Shi J, Fan T, Shan YY, et al. Trends and correlation of antibacterial usage and bacterial resistance: time series analysis for antibacterial stewardship in a Chinese teaching hospital (2009–2013). Eur J Clin Microbiol Infect Dis. 2015;34:795–803.CrossRefPubMed
20.
go back to reference Chanawong A, M’Zali FH, Heritage J, Xiong JH, Hawkey PM. Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People’s Republic of China. Antimicrob Agents Chemother. 2002;46:630–7.CrossRefPubMedPubMedCentral Chanawong A, M’Zali FH, Heritage J, Xiong JH, Hawkey PM. Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People’s Republic of China. Antimicrob Agents Chemother. 2002;46:630–7.CrossRefPubMedPubMedCentral
21.
go back to reference Wang H, Kelkar S, Wu W, Chen M, Quinn JP. Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China. Antimicrob Agents Chemother. 2003;47:790–3.CrossRefPubMedPubMedCentral Wang H, Kelkar S, Wu W, Chen M, Quinn JP. Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China. Antimicrob Agents Chemother. 2003;47:790–3.CrossRefPubMedPubMedCentral
22.
go back to reference Yang Q, Zhang H, Cheng J, Xu Z, Xu Y, Cao B, et al. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum beta-lactamases in China. Int J Antimicrob Agents. 2015;45:485–90.CrossRefPubMed Yang Q, Zhang H, Cheng J, Xu Z, Xu Y, Cao B, et al. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum beta-lactamases in China. Int J Antimicrob Agents. 2015;45:485–90.CrossRefPubMed
23.
go back to reference Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect. 2008;14 Suppl 1:159–65.CrossRefPubMed Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect. 2008;14 Suppl 1:159–65.CrossRefPubMed
24.
go back to reference Bush K. Extended-spectrum beta-lactamases in North America, 1987–2006. Clin Microbiol Infect. 2008;14 Suppl 1:134–43.CrossRefPubMed Bush K. Extended-spectrum beta-lactamases in North America, 1987–2006. Clin Microbiol Infect. 2008;14 Suppl 1:134–43.CrossRefPubMed
25.
go back to reference Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother. 2001;45:1515–21.CrossRefPubMedPubMedCentral Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother. 2001;45:1515–21.CrossRefPubMedPubMedCentral
26.
go back to reference Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682–90.CrossRefPubMed Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682–90.CrossRefPubMed
27.
go back to reference Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother. 2001;45:2831–7.CrossRefPubMedPubMedCentral Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother. 2001;45:2831–7.CrossRefPubMedPubMedCentral
28.
go back to reference Essack SY. Treatment options for extended-spectrum beta-lactamase-producers. FEMS Microbiol Lett. 2000;190:181–4.PubMed Essack SY. Treatment options for extended-spectrum beta-lactamase-producers. FEMS Microbiol Lett. 2000;190:181–4.PubMed
29.
go back to reference Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460–3.CrossRefPubMed Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460–3.CrossRefPubMed
30.
go back to reference Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother. 2006;50:3396–406.CrossRefPubMedPubMedCentral Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother. 2006;50:3396–406.CrossRefPubMedPubMedCentral
31.
go back to reference Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165:1430–5.CrossRefPubMed Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165:1430–5.CrossRefPubMed
32.
go back to reference Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence. Euro Surveill. 2008;13. Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence. Euro Surveill. 2008;13.
33.
go back to reference Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Papahatzaki H, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect. 2009;58:213–9.CrossRefPubMed Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Papahatzaki H, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect. 2009;58:213–9.CrossRefPubMed
34.
go back to reference Keller R, Pedroso MZ, Ritchmann R, Silva RM. Occurrence of virulence-associated properties in Enterobacter cloacae. Infect Immun. 1998;66:645–9.PubMedPubMedCentral Keller R, Pedroso MZ, Ritchmann R, Silva RM. Occurrence of virulence-associated properties in Enterobacter cloacae. Infect Immun. 1998;66:645–9.PubMedPubMedCentral
35.
go back to reference Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob Agents Chemother. 2010;54:573–7.CrossRefPubMed Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob Agents Chemother. 2010;54:573–7.CrossRefPubMed
36.
go back to reference Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis. 2015;15:414.CrossRefPubMedPubMedCentral Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis. 2015;15:414.CrossRefPubMedPubMedCentral
Metadata
Title
Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014
Authors
Qiwen Yang
Hui Zhang
Yao Wang
Zhipeng Xu
Ge Zhang
Xinxin Chen
Yingchun Xu
Bin Cao
Haishen Kong
Yuxing Ni
Yunsong Yu
Ziyong Sun
Bijie Hu
Wenxiang Huang
Yong Wang
Anhua Wu
Xianju Feng
Kang Liao
Yanping Luo
Zhidong Hu
Yunzhuo Chu
Juan Lu
Jianrong Su
Bingdong Gui
Qiong Duan
Shufang Zhang
Haifeng Shao
Robert E. Badal
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2296-x

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue